Molnupiravir (EIDD-2801) and EIDD-1931 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing viral load in various tissues.
Does molnupiravir and its active form EIDD-1931 reduce viral load and protect against lethal enterovirus infection in preclinical models?
Molnupiravir and its active form EIDD-1931 demonstrate potent antiviral activity against enterovirus infections in vitro and in vivo, suggesting potential as a therapeutic candidate.
Enterovirus infections can cause hand, foot, and mouth disease (HFDM), aseptic meningitis, encephalitis, myocarditis, and acute flaccid myelitis, leading to death of infants and young children. However, no specific antiviral drug is currently available for the treatment of this type of infection. The Unites States and United Kingdom health authorities recently approved a new antiviral drug, molnupiravir, for the treatment of COVID-19. In this study, we reported that molnupiravir (EIDD-2801) and its active form, EIDD-1931, have broad-spectrum anti-enterovirus potential. Our data showed that EIDD-1931 could significantly reduce the production of EV-A71 progeny virus and the expression of EV-A71 viral protein at non-cytotoxic concentrations. The results of the time-of-addition assay suggest that EIDD-1931 acts at the post-entry step, which is in accordance with its antiviral mechanism. The intraperitoneal administration of EIDD-1931 and EIDD-2801 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing the viral load in various tissues of the infected mice. The pharmacokinetics analysis indicated that the plasma drug concentration overwhelmed the EC50 for enteroviruses, suggesting the clinical potential of molnupiravir against enteroviruses. Thus, molnupiravir along with its active form, EIDD-1931, may be a promising drug candidate against enterovirus infections.
Li et al. (Wed,) conducted a other in Enterovirus infections. Molnupiravir (EIDD-2801) and EIDD-1931 was evaluated on Protection from lethal EV-A71 challenge and viral load reduction. Molnupiravir (EIDD-2801) and EIDD-1931 protected 1-day-old ICR suckling mice from lethal EV-A71 challenge by reducing viral load in various tissues.